Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 52

1.

Effect of intravenous immunoglobulin on the function of Treg cells derived from immunosuppressed mice with Pseudomonas aeruginosa pneumonia.

Li J, Chen T, Yuan C, Zhao G, Xu M, Li X, Cao J, Xing L.

PLoS One. 2017 May 8;12(5):e0176843. doi: 10.1371/journal.pone.0176843. eCollection 2017.

2.

Engineering Chimeric Antigen Receptor T-Cells for Racing in Solid Tumors: Don't Forget the Fuel.

Irving M, Vuillefroy de Silly R, Scholten K, Dilek N, Coukos G.

Front Immunol. 2017 Apr 3;8:267. doi: 10.3389/fimmu.2017.00267. eCollection 2017. Review.

3.

Molecular Pathways: Oncologic Pathways and Their Role in T-cell Exclusion and Immune Evasion-A New Role for the AXL Receptor Tyrosine Kinase.

Aguilera TA, Giaccia AJ.

Clin Cancer Res. 2017 Jun 15;23(12):2928-2933. doi: 10.1158/1078-0432.CCR-17-0189. Epub 2017 Mar 13.

PMID:
28289089
4.

Clinical response in patients with ovarian cancer treated with metronomic chemotherapy.

Perroud HA, Scharovsky OG, Rozados VR, Alasino CM.

Ecancermedicalscience. 2017 Feb 28;11:723. doi: 10.3332/ecancer.2017.723. eCollection 2017.

5.

A randomized phase II trial of personalized peptide vaccine with low dose cyclophosphamide in biliary tract cancer.

Shirahama T, Muroya D, Matsueda S, Yamada A, Shichijo S, Naito M, Yamashita T, Sakamoto S, Okuda K, Itoh K, Sasada T, Yutani S.

Cancer Sci. 2017 May;108(5):838-845. doi: 10.1111/cas.13193. Epub 2017 May 5.

6.

Regulatory T cells in cancer immunotherapy.

Tanaka A, Sakaguchi S.

Cell Res. 2017 Jan;27(1):109-118. doi: 10.1038/cr.2016.151. Epub 2016 Dec 20. Review.

PMID:
27995907
8.

Radiotherapy: Changing the Game in Immunotherapy.

Demaria S, Coleman CN, Formenti SC.

Trends Cancer. 2016 Jun;2(6):286-294.

9.

Synergistic antitumor efficacy of antibacterial helvolic acid from Cordyceps taii and cyclophosphamide in a tumor mouse model.

Xiao JH, Zhang Y, Liang GY, Liu RM, Li XG, Zhang LT, Chen DX, Zhong JJ.

Exp Biol Med (Maywood). 2017 Jan;242(2):214-222. doi: 10.1177/1535370216668051. Epub 2016 Oct 4.

10.

Cubosome nanoparticles potentiate immune properties of immunostimulants.

Liu Z, Luo L, Zheng S, Niu Y, Bo R, Huang Y, Xing J, Li Z, Wang D.

Int J Nanomedicine. 2016 Jul 29;11:3571-83. doi: 10.2147/IJN.S110406. eCollection 2016.

11.

The role of regulatory T cells in cancer immunology.

Whiteside TL.

Immunotargets Ther. 2015 Aug 5;4:159-71. doi: 10.2147/ITT.S55415. eCollection 2015. Review.

12.

Therapeutic cancer vaccines and combination immunotherapies involving vaccination.

Nguyen T, Urban J, Kalinski P.

Immunotargets Ther. 2014 Oct 6;3:135-50. doi: 10.2147/ITT.S40264. eCollection 2014. Review.

13.

Cancer immunotherapy: the beginning of the end of cancer?

Farkona S, Diamandis EP, Blasutig IM.

BMC Med. 2016 May 5;14:73. doi: 10.1186/s12916-016-0623-5. Review.

14.

Novel immunotherapeutic approaches for the treatment of acute leukemia (myeloid and lymphoblastic).

Ishii K, Barrett AJ.

Ther Adv Hematol. 2016 Feb;7(1):17-39. doi: 10.1177/2040620715616544. Review.

15.

Effects of radiation on T regulatory cells in normal states and cancer: mechanisms and clinical implications.

Liu S, Sun X, Luo J, Zhu H, Yang X, Guo Q, Song Y, Sun X.

Am J Cancer Res. 2015 Oct 15;5(11):3276-85. eCollection 2015. Review.

16.

Third-Line Chemotherapy for Metastatic Urothelial Cancer: A Retrospective Observational Study.

Di Lorenzo G, Buonerba C, Bellelli T, Romano C, Montanaro V, Ferro M, Benincasa A, Ribera D, Lucarelli G, De Cobelli O, Sonpavde G, De Placido S.

Medicine (Baltimore). 2015 Dec;94(51):e2297. doi: 10.1097/MD.0000000000002297.

17.

CpG-1826 immunotherapy potentiates chemotherapeutic and anti-tumor immune responses to metronomic cyclophosphamide in a preclinical glioma model.

Jordan M, Waxman DJ.

Cancer Lett. 2016 Apr 1;373(1):88-96. doi: 10.1016/j.canlet.2015.11.029. Epub 2015 Dec 3.

18.

Survivin-targeted immunotherapy drives robust polyfunctional T cell generation and differentiation in advanced ovarian cancer patients.

Berinstein NL, Karkada M, Oza AM, Odunsi K, Villella JA, Nemunaitis JJ, Morse MA, Pejovic T, Bentley J, Buyse M, Nigam R, Weir GM, MacDonald LD, Quinton T, Rajagopalan R, Sharp K, Penwell A, Sammatur L, Burzykowski T, Stanford MM, Mansour M.

Oncoimmunology. 2015 May 7;4(8):e1026529. eCollection 2015 Aug.

19.

Regulatory T cells, inherited variation, and clinical outcome in epithelial ovarian cancer.

Knutson KL, Maurer MJ, Preston CC, Moysich KB, Goergen K, Hawthorne KM, Cunningham JM, Odunsi K, Hartmann LC, Kalli KR, Oberg AL, Goode EL.

Cancer Immunol Immunother. 2015 Dec;64(12):1495-504. doi: 10.1007/s00262-015-1753-x. Epub 2015 Aug 23.

20.

The Concept of Hormesis in Cancer Therapy - Is Less More?

Gaya A, Akle CA, Mudan S, Grange J.

Cureus. 2015 Apr 2;7(4):e261. doi: 10.7759/cureus.261. eCollection 2015 Apr. Review.

Supplemental Content

Support Center